Traffic Thera, Inc. ("Traffic") is an early-stage biotech company that is advancing a technology platform to enable the precision manufacturing of Ab-drug conjugates (ADCs) as targeted therapies for cancer and inflammatory disorders. Traffic has developed a site-specific chemoenzymatic approach that generates homogeneous ADCs with (1) completely controllable conjugation site and ratio, and (2) a diverse range of linker chemistries and toxic payloads. To date, Traffic has secured IP rights to its core technologies, published foundational papers on this novel manufacturing approach, established expertise in the rational design of targeted Ab scaffolds, and is progressing several corporate pharma partnerships to co-develop ADCs from monoclonal and bispecific Abs that have already been advanced through IND-enabling studies. We are seeking seed investors with global professional networks and experience in biologics development, industrial biomanufacturing and clinical trial design.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Bispecific Antibody-Drug Conjugate (ADC)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):